Streamlined Workflow for Fragment Based Screening by NMR

NMR binding assays are routinely applied for hit finding and validation during the early stages of drug discovery, particularly for fragment-based lead generation. Weak binding affinities in the μM to mM range are a hallmark of fragments that are valuable starting points for medicinal chemistry development programs. Appropriate automated screening and analysis methods are now available for the detection of binding fragments.

During this webinar, we will demonstrate an all-around solution for Fragment Based Screening (FBS) by linking Bruker’s automated data acquisition methods and MestreLab’s automated data analysis software tools. This combination includes:

1) A quality check of the fragment library by automated structure verification and qNMR tests using the reference spectra, and identification of any compounds that have suspicious quality, identity, or have low solubility
2) Pooling of fragments into optimized cocktails through minimization of peak overlap
3) Automated acquisition and visualization of 1H or 19F FBS NMR experiment screening data
4) Batch processing and automated analysis of FBS spectra to identify hits, and automated analysis of 2D chemical shift perturbation spectra to calculate Kd.

For every stage of the workflow, software tools are also provided to enable manual verification of the automation results.

What You Will Discover

In this webinar, Fabrice Moriaud, Ph.D. from Bruker BioSpin and Mitcheel Maestre Martinez, Ph.D. from MestreLab Research will outline the integration of Bruker’s Fragment-Based Screening (FBS) solution with Mestrelab’s Screen software. This combination provides drug discovery groups with an integrated experience from data acquisition and analysis to the identification of hits in FBS-by-NMR campaigns. Practical aspects will be emphasized.

Key Points

  • NMR based strategy to accelerate lead discovery with confidence
  • Complete tool box for fragment based screening by NMR
  • Fully Automated workflow, from spectal acquisition through to results

Who Should Attend?

This webinar will be of interest to anyone working in drug discovery, whether it be in the pharmaceutical industry, contract research organizations or academia, including those with no prior experience in FBS.

Speakers

Dr. Fabrice Moriaud

Product Manager for GxP solutions, Bruker BioSpin

Fabrice Moriaud, Ph.D. is Product Manager for GxP solutions. In his role as Solutions Development Manager at Bruker BioSpin, he brings extensive experience in leading the development of solutions for the Pharma industry. Trained as a chemist, Fabrice has a strong academic background in EPR and NMR.

Dr. Mitcheell Maestre-Martinez

Product Manager – MestreLab Research, Santiago de Compostela

Mitcheell Maestre-Martinez, Ph.D. is the product manager and developer of Mnova Screen. He has extensive experience in the application of NMR to the study of proteins and their interactions, with strong focus on software development for automation and data analysis. He is a chemist by training with an academic background in NMR and structural biology.

Registration

Input value is invalid.

Are you already in contact with your Bruker representative regarding any product inquiries?

We constantly want to improve our service for our customers. In answering the following question you help us to serve your needs even better in the future: What best describes your situation?

To learn how Bruker handles my personal data, please read Bruker´s Privacy Notice and  Terms of Use.

I agree to share my contact details with Bruker Corporation and its affiliates within the Bruker Group for the purpose of proceeding with my registration.

Already registered and lost your invitation link?

Thank you. The invitation link has been resent.